Outrun emerges from stealth with $10M for E3 ligase inhibitors
Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting an E3 ligase that tags a tumor suppressor protein for destruction will now advance to preclinical development.
Newco Outrun Therapeutics Ltd Newco Outrun Therapeutics Protein Degradation E3 Ligase Inhibitors Outrun Therapeutics Ltd Protein Stabilization
Source: bioworld.com